

MIT Open Access Articles

High-throughput nuclear delivery and rapid expression of DNA via mechanical and electrical cell-membrane disruption

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

Citation: Ding, Xiaoyun, et al. "High-Throughput Nuclear Delivery and Rapid Expression of DNA via Mechanical and Electrical Cell-Membrane Disruption." *Nature Biomedical Engineering* 1, 3 (March 2017): 0039 © 2017 Macmillan Publishers Limited, part of Springer Nature

As Published: <http://dx.doi.org/10.1038/s41551-017-0039>

Persistent URL: <http://hdl.handle.net/1721.1/111022>

Version: Author's final manuscript: final author's manuscript post peer review, without publisher's formatting or copy editing

Terms of Use: Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.



1 **High-throughput Nuclear Delivery and Rapid Expression of DNA**
2 **via Mechanical and Electrical Cell Membrane Disruption**

3 **Xiaoyun Ding^{1,2,a}, Martin Stewart^{1,2,a}, Armon Sharei^{1,2}, James C. Weaver³,**
4 **Robert S. Langer^{1,2,*}, and Klavs F. Jensen^{1,*}**

6 ¹ Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA
7 02139, USA

8 ² The David Koch Institute for Integrative Cancer Research, Massachusetts Institute of
9 Technology, Cambridge, MA 02139, USA

10 ³ Harvard–MIT Division of Health Sciences and Technology, Massachusetts Institute of
11 Technology, Cambridge, MA 02139, USA

12 ^a These authors contributed equally to this work

13 ^{*} To whom correspondence should be addressed. Email: rlanger@mit.edu, kfjensen@mit.edu.

1 **ABSTRACT**

2 Nuclear transfection of DNA into mammalian cells is challenging yet critical for many biological
3 and medical studies. Here, by combining cell squeezing and electric-field-driven transport in a
4 device that integrates microfluidic channels with constrictions and microelectrodes, we
5 demonstrate nuclear delivery of plasmid DNA within 1 hour after treatment, the most rapid DNA
6 expression in a high-throughput setting (up to millions of cells per minute per device). Passing
7 cells at high speed through microfluidic constrictions smaller than the cell diameter mechanically
8 disrupts the cell membrane, allowing a subsequent electric field to further disrupt the nuclear
9 envelope and drive DNA molecules into the cytoplasm and nucleus. By tracking the localization
10 of the ESCRT-III (endosomal sorting complexes required for transport) protein CHMP4B, we
11 show that the integrity of the nuclear envelope is recovered within 15 minutes of treatment. We
12 also provide insight into subcellular delivery by comparing the performance of the disruption-
13 and-field-enhanced method with those of conventional chemical, electroporation, and manual-
14 injection systems.

15

1
2 Intracellular delivery, the introduction of exogenous materials into cells, is essential to many
3 studies in basic biology and biomedical research (1, 2). A multitude of techniques exists for cell
4 transfection, including biological, chemical, and physical methods (3). Biological/chemical
5 methods usually rely on carriers such as viruses, vesicles, peptides or nanoparticles (4-7).
6 Physical methods primarily use membrane-disruption techniques such as microinjection,
7 electroporation, laser optoporation, and particle bombardment for gene delivery (8-13). Although
8 electroporation has been widely used for DNA transfection since the early 1980s, the underlying
9 mechanism of delivery is not completely understood in nucleated mammalian cells (14-19). In
10 the electroporation process, DNA molecules accumulate and interact with the
11 electropermeabilized plasma membrane during the electric pulse to form aggregates. Afterwards,
12 those DNA aggregates are internalized into the cytoplasm and subsequently expressed (20-26). It
13 is unlikely that DNA plasmids navigate through the viscous and crowded cytoplasm to reach the
14 nucleus simply by diffusion (27, 28). Microtubule and actin networks have been proposed to play
15 an important role in DNA transportation within the cytoplasm, and the time-scale of such
16 processes can be hours long depending on the cell type (22). The lack of detailed mechanistic
17 understanding and the complex nature of DNA transfer between the plasma membrane and
18 nucleus limit our ability to enhance electroporation performance. Moreover, the strong fields
19 used in current electroporation techniques can lead to significant damage or death (25, 26). Nano
20 structure based methods have demonstrated potential for effective gene transfection by
21 penetrating DNA-loaded nanoneedles into the cell, or by diffusion/electrophoresis through a
22 nanostraw (29-31). However, such methods typically have relatively low throughput. Moreover,
23 the nuclear envelope rupture is not well investigated. Hence, substantial interest remains in
24 creating techniques that can quickly and directly deliver DNA to the nucleus in a large number of
25 cells with controllable nuclear envelope damage.

26 One example of a feasible strategy would involve the transient disruption of the cell plasma
27 membrane and nuclear envelope followed by entry of the target material before resealing. Cell
28 squeezing is a representative technique that enables delivery of a diversity of materials to
29 numerous cell types by mechanically disrupting the plasma membrane and allowing diffusion to
30 transport materials of interest into the cell cytosol (32-35). DNA delivery is, however, more
31 complicated because DNA must enter the nucleus to perform its function and the cytosolic

1 delivery results in the degradation of DNA before it can reach the nucleus, as reported for
2 microinjection (11). Thus, passive diffusion of DNA is likely insufficient and active transport of
3 the DNA to the nucleus is necessary to initiate gene expression. To address this challenge, we
4 combine disruption of both plasma membrane and nuclear envelope with electric fields to
5 enhance delivery – Disruption and Field Enhanced (DFE) delivery. Recent studies show that
6 moderate nuclear envelope rupture could be rapidly repaired in an ESCRT (endosomal sorting
7 complexes required for transport)-dependent manner, indicating a potential of reversible nuclear
8 envelope rupture (36-39). Here, we use a microfluidic device to create rapid mechanical
9 deformation by cell squeezing to disrupt the plasma membrane, followed by exposing the cell to
10 an electric field that generates reversible nuclear envelope rupture and drives the negatively
11 charged DNA into the nucleus and cytoplasm. With this device, we show a significant increase
12 in efficiency and speed of DNA expression, as well as rapid nuclear localization akin to
13 microinjection. Moreover, DNA plasmids are successfully delivered to both nucleus and
14 cytoplasm at throughputs up to millions of cells per minute per device in continuous flow. We
15 further investigate the disruption and repair of both plasma membrane and nuclear envelope, and
16 their relation to intracellular and nuclear delivery. The DFE system also proves useful in co-
17 delivery of DNA, RNA, and proteins.

18 **DFE Design and Characterization**

19 In order to explore whether addition of an electric field would be able to promote delivery of
20 DNA after squeezing, we constructed a microfluidic device with an electric pulse zone
21 downstream of the constriction zone (Figure 1). Each device consisted of a set of parallel,
22 identical constriction channels and a set of electrodes. Consistent with the existing squeeze
23 design (32), 75 parallel channels with constriction zones were etched into a silicon wafer using
24 deep reactive ion etching (DRIE). Subsequently, electrodes were incorporated into the DFE
25 device section by anodic bonding of Pyrex patterned with electrodes (see figure S1 for more
26 details of fabrication). Based on our previous observation for the best efficiency in intracellular
27 delivery (32, 33) with cell squeezing, the width and length of the constriction were in the ranges
28 4 - 10 μm and 10 - 30 μm , respectively. The length, width, and gap space between each electrode
29 were 8 mm, 60 μm , and 40 μm , respectively, allowing the generation of sufficiently high electric
30 field (~ 2 kv/cm) with low applied voltage. The duration and duty cycle of the electrical pulse

1 applied to the device ranged from 50 - 500 μ s and 1% - 10%, commensurate with values
2 commonly used for electroporation (26).

3 We typically operated the DFE device at a throughput of 100 000 – 500 000 cells/s per chip per
4 run (each run took 5-20 seconds). Each data point was the mean value of three collections. Each
5 device could be reused 5-10 times before cell debris clogged the channels. At that point, devices
6 were cleaned for reuse by flushing the device with 10% bleach buffer. A 50 – 100 μ L mixture of
7 cells and materials to be delivered was placed into the inlet reservoir and driven through the
8 device with nitrogen pressure controlled by a regulator (32). The exposure time of the cells in the
9 electrical field typically ranged from 10 – 100 ms, depending on the flow rate.

10 Many parameters governed the performance of mechanical disruption and electrical delivery,
11 including cell speed, constriction dimension, electrical pulse profile, strength, and number of
12 pulses. We first performed a number of experiments to characterize DNA transfection with the
13 DFE technique by treating a mixture of HeLa cells and GFP plasmid DNA at different pulse
14 amplitudes. After treatment, cells were incubated at 37 °C for 24 hours. GFP fluorescence
15 measurements by flow cytometry characterized DNA expression. These experiments used a
16 device with a constriction length of 10 μ m and a constriction width of 6 μ m, denoted as a 10-6
17 DFE device. Our experimental results show that cell transfection reached above 60% and 90%
18 when the applied amplitude increased to 8V and 10V respectively (Figure 2a red columns). As a
19 control group, we treated cells using a device with the same electrical field and cell speed but no
20 constriction structure (squeezing), corresponding to electroporation in microfluidic devices (flow
21 EP). With cells experiencing only an electric field, the DNA transfection efficacy reached 60%
22 after the applied amplitude increased to 14V (Figure 2a green columns). Both cases had similar
23 cell viability (Figure 2b), suggesting that mechanical disruption dramatically enhanced the DNA
24 delivery at lower field intensities while causing negligible additional damage to the cells.

25 We also investigated the influence of cell speed on the transfection. Under an applied pulse of
26 10V, the DNA expression decreased with increasing cell speed due to the reduced number of
27 pulses the cell received as it traveled through the electric field (Figure S2). At cell speeds ~300
28 mm/s, cell viability and DNA expression seem to best balance severe electric damage at low
29 speed and mechanical damage at high speed. The delivery efficiency of membrane-impermeable
30 Cascade Blue labeled 3-kDa dextran molecules to live HeLa cells first dropped and then grew
31 with increasing cell speed, indicating the dominant mechanism of delivery for this molecule

1 switches from electrical field at low speed to mechanical disruption at high speed. The difference
2 in delivery behavior between the 3kDa dextran and DNA molecules further highlight the
3 significance of electrical field effect for DNA transfection.

4 **DFE versus Microinjection, Flow EP, EP, and Cell Squeezing**

5 In order to gain further insight into the mechanism of DFE delivery, we carried out a
6 comparative study with four widely used DNA transfection techniques: microinjection
7 (Eppendorf microinjector 5242), Lipofection (lipofectormine 2000 from ThermoFisher), flow EP
8 (microfluidics-based flow electroporation) and EP (conventional electroporation, using the
9 NEON electroporation system from ThermoFisher, a common commercial electroporation tool).
10 DNA expression was analyzed using flow cytometry after treatment with each technique. EP and
11 flow EP showed similar expression kinetics as GFP gradually expressed throughout 24 hours
12 after treatment (Figure 2 c and d). 70% of GFP expressing cells (cells that express GFP
13 fluorescence after 48 hours) expressed GFP between 4-48 hours. In contrast, with microinjection
14 and DFE, more than 80% of GFP expressing cells had measureable expression within the first
15 hour post treatment, indicating that DNA transcription/translation occurred soon after treatment.
16 The remaining 20% of ultimately GFP expressing cells had detectable expression 1 to 4 hours
17 post treatment. Microinjection is broadly accepted as a means of facilitating direct injection of
18 materials into the nucleus. The similar DNA expression kinetics for microinjection and DFE
19 suggest that DNA delivered by DFE becomes accessible for transcription in the nucleus.
20 For the Lipofection case, we found minimal GFP fluorescence in the first 4 hours post treatment,
21 and more than 95% of transfected cells expressed GFP between 4 – 48 h after treatment.
22 Fluorescence images of GFP expressed cells by DFE, EP, and Lipofection are shown in Figure
23 S3. We further compared the fluorescence intensity of GFP in Hela cells as measured by flow
24 cytometry (Figure S4). The DFE data display a peak in the fluorescence intensity that keeps
25 increasing in intensity within the first 4 hours after treatment indicating that the DNA
26 transcription/translation in most of cells occurred from a similar starting time point soon after
27 treatment. In contrast, for EP and Lipofection, the fluorescence intensity has a flat distribution in
28 the first 12 hours, suggesting that the time required for the DNA migration to nucleus and release
29 from carrier varies from 4 to 24 hours or even longer. DFE has lower RSD (relative standard
30 deviation) and higher NMI (normalized mean intensity) than EP, indicating DFE has better

1 transfection uniformity and level (more transfection) than EP. Lipofection has the highest NMI,
2 which could be due to the fact the DNA molecules are confined in lipid nano particles while in
3 DFE and EP DNA molecules are distributed throughout the solution.

4 To further explore the working mechanism of DFE, we directly visualized the distribution of
5 DNA at single cell level using CY3 labeled plasmid DNA (Figure 3). Cells were first incubated
6 with DAPI (ThermoFisher) and Cell Mask green plasma membrane stain (ThermoFisher) for
7 nuclear and membrane staining, and then mixed with labeled DNA right before treatment with
8 DFE, EP, and Squeezing. After treatment, cells were incubated in culture medium for 3-5
9 minutes and then fixed. Optical measurements were carried out using a Nikon A1R confocal
10 microscope. When an electric pulse of 15ms/1200V, known to permeabilize cells, was applied in
11 NEON electroporation system, a sharp CY3 fluorescence spots appeared at the plasma
12 membrane level, indicating the absorption and accumulation of DNA on the membrane (Figure
13 3b, see Figure S5 for additional results). This result is consistent with previous studies that
14 demonstrate embedding of DNA into the plasma membrane. In Squeezing, no fluorescence of
15 labeled DNA was detected in the cytoplasm with the confocal microscope. In DFE, we found
16 labeled DNA fluorescence distributed in the cytoplasm, nucleus, and plasma membrane (Figure
17 3c, see Figure S6 for additional results). The bright spots on the plasma membrane are DNA
18 complexes formed as in conventional electroporation. Importantly, the direct visualization of
19 DNA in the cytoplasm and nucleus further supports the hypothesis that DFE is capable of more
20 effective delivery of DNA and indicates that the mechanism of action of the DFE system is likely
21 distinct from electroporation or squeezing alone. These observations are further characterized by
22 the relative fluorescence intensity profiles (Figure 3d) showing the DNA distribution along the
23 dashed line across the single cells in Figures 3 a-c treated by squeezing, EP, and DFE. The
24 higher fluorescence intensity in the nucleus than in cytoplasm after DFE could be attributed to
25 (1) degradation of DNA in the cytoplasm by the surrounding DNase and subsequent outward
26 diffusion of Cy3 dye detached from the degraded DNA; or (2) more DNA trapping in the dense
27 nucleus than surrounding cytosol as DNA transits through the cell in the electric field. Combined
28 with our observations of rapid DNA expression, either case demonstrates that disruption and
29 field enhanced delivery facilitates efficient delivery of DNA directly to the nucleus.

30 The ESCRT III complex is involved in repair of both plasma membrane and nuclear envelope
31 rupture (36-39). We used HeLa cells expressing GFP-tagged CHMP4B, an important ESCRT III

1 complex subunit, to study the nuclear envelope rupture and repair in DFE. We can induce
2 recruitment of CHMP4B-GFP at the wounding site near the nuclear envelope using
3 microinjection (Figure S7). In DFE, CHMP4B-GFP formed transient foci at the site of both
4 nuclear envelope and plasma membrane (Figure 4a). In EP and Squeezing, CHMP4B-GFP was
5 only recruited to plasma membrane. CHMP4B-GFP localized to the site of both plasma and
6 nuclear membrane at 1-2 minutes right after membrane disruption to repair damage, and
7 decreased after resealing (Figure 4 b and c, figure S8). This suggests that DFE could generate
8 reversible disruption on both plasma membrane and nuclear envelope, a critical step for nuclear
9 delivery.

10 **Discussion**

11 Intracellular delivery of nucleic acids is a challenging first step for an abundance of biological
12 studies and applications. However, the current leading methods for DNA transfection, such as
13 electroporation and lipofection, rely on a delayed trafficking of DNA to the nucleus. On the other
14 hand, mechanical and other permeabilization techniques that deliver DNA directly to the
15 cytoplasm often fail to achieve nuclear penetration and subsequent expression. Here, the
16 proposed DFE concept combines the efficacy of mechanical membrane disruption with the
17 driving force of a field – thus potentially maintaining the robust and rapid delivery capabilities of
18 mechanical disruption while enhancing nuclear delivery of plasmids. DFE performance is likely
19 a nonlinear combination of mechanical disruption and electrical delivery, each of which are
20 influenced by complex sets of parameters. The choice of the buffer solution medium is a
21 challenge. Commercial available buffers (including electroporation buffer from NEON and
22 Eppendorf) works well for electric delivery, but not for cell squeezing based membrane
23 disruption. Phosphate buffered saline (PBS) works well for cell squeezing, but not for electric
24 delivery owing to its high conductivity, which produces electrolytic effects including changes in
25 temperature, pH, and the chemical composition of the solution in proportion to the applied
26 voltage. The hypo-osmolar buffer we used here is compatible with both mechanical disruption
27 and electric delivery process. As expected, we found that hypo-osmolar buffer enlarged cell size,
28 made the plasma membrane more susceptible to disruption (40), and subsequently lowered the
29 cell velocity required for mechanical disruption. The use of hypo-osmolar buffer also facilitated

1 effective electric delivery (41). Lower electric field strength for electric delivery could be used at
2 low cell speeds to protect electrodes and avoid electrolysis.

3 DNA transport from plasma membrane to nucleus and subsequent transcription is a complex,
4 most likely active, process that can take hours and may vary dramatically among different cell
5 types. This process is essential in electroporation and carrier-based methods such as Lipofection.
6 We have demonstrated that DFE is able to deliver DNA directly into the nucleus by providing a
7 driving force to move DNA across a mechanically disrupted plasma membrane. The mechanical
8 disruption decreases the plasma membrane barrier function to achieve an enhanced electrical
9 delivery. The post-squeezing electric field might also alter distribution of openings in the
10 membrane (42), to facilitate intracellular delivery. To our knowledge, the DFE experiments
11 represent the most rapid expression of plasmid DNA in a high throughput setting (up to a few
12 million cells per device per minute). The throughput could be further improved by adding more
13 parallel microchannels on the chip or operating multiple devices in parallel. As shown in Fig. S2,
14 the increase of diffusion-based delivery coincided with decreasing DNA transfection when
15 increasing cell speed, this is due to the inverse dependence between cell squeezing speed and
16 electric field exposure. High cell speed enhances strong mechanical disruption and thus more
17 diffusive delivery, it also leads to a shorter exposure time in the electric field, causing lower
18 electrical field driven delivery. Such interdependence is a limitation of the current version of the
19 device.

20 The DNA expression dynamics of Lipofection in Figures 2 c and d reveal that DNA transfer to
21 the nucleus and subsequent transcription can require over 4 hours in Hela cells. DNA expression
22 with conventional electroporation was slightly faster. There is ongoing debate regarding how
23 DNA migrates into the nucleus during the electroporation process (15). Some hypothesize that
24 electric pulse permeabilizes the cell membrane and electrophoresis drives DNA directly into the
25 nucleus, while others observe that DNA first form aggregates at electropermeabilized areas of
26 the plasma membrane during electric pulse and then migrates toward the nucleus through a
27 biologically active process (17, 18, 25, 26). In our EP results, 20% of transfected cells expressed
28 GFP within the first hour and 80% expressed throughout the next 20 hours. This could be an
29 indication that both of the aforementioned mechanisms occurred in EP. The small portion of
30 cells that express GFP immediately after treatment may involve direct electrophoresis of DNA
31 into the nucleus while the majority of cells that expressed GFP after 4 hours must first transport

1 the DNA to the nucleus for expression, as in the case of Lipofection. Future studies could
2 integrate a cell trap structure in the electric field downstream of the mechanical disruption to
3 visualize DNA migration through the mechanically induced disruption in the plasma membrane.
4 Recently ESCRT-III proteins have been shown to be involved in both plasma and nuclear
5 membrane repair (36-39). We used HeLa cells expressing GFP-tagged CHMP4B, an important
6 subunit of ESCRT-III complex, to monitor and measure the membrane dynamics in DFE. The
7 recruitment of CHMP4B-GFP foci at both plasma and nuclear membrane after DFE treatment
8 reveals that both membrane systems were disrupted and resealed, which is a critical step for
9 nuclear delivery. In Squeezing and EP, however, CHMP4B-GFP only localized at the plasma
10 membrane, indicating that nuclear envelope rupture did not occur at detectable levels. ESCRT
11 proteins, including CHMP4B, are involved in the repair of small membrane wounds less than
12 100 nm (36). This may explain why fewer CHMP4B-GFP foci were observed after squeezing
13 compared to EP and DFE. It is known that electric fields usually generate pores in the range of a
14 few nm or tens of nm, while mechanical disruption in Squeezing at high flow rates could
15 generate larger wounds or prompt membrane plasma repair via pathways other than ESCRT-
16 mediated processes (32). The recruitment of CHMP4B-GFP to both plasma and nuclear
17 membrane wounds occurred from 1-2 minutes after the disruption, and nuclear membrane repair
18 was completed by about 10-15 minutes post disruption, about 5 minutes slower than plasma
19 membrane resealing. Such repair dynamics are consistent with recently published reports (36-
20 38).

21 DFE delivery combines microfluidic-based membrane disruption and field effects to achieve
22 potentially greater efficacy than either individual approach. The mechanical disruption
23 techniques, such as squeezing, have shown significant success in delivery of a variety of
24 materials, including proteins and nanomaterials, to a diversity of cell types with minimal toxicity,
25 but have had limited success with DNA, presumably due to ineffective nuclear delivery. In DFE,
26 we have demonstrated a successful co-delivery of DNA plasmid, mRNA, and protein (APC
27 mouse IgG1 k Isotype Ctrl antibody, Figure S9). The results show that DNA and mRNA are
28 significantly dependent on the electric field, while the protein delivery is more dependent on
29 mechanical disruption. In mouse Embryonic Stem Cells (mESC), we achieved DNA transfection
30 of 19% and 36% at 10V and 14V respectively in DFE (Figure S10 a-c). By combining
31 mechanical disruption and electric field effects, our DFE concept has demonstrated reversible

1 nuclear and plasma membrane disruption for both nuclear and cytosolic delivery, and is capable
2 of co-delivering proteins and nucleic acids, characteristics that are difficult to accomplish with
3 any of the aforementioned methods individually.

4 **Outlook**

5 Our DFE system is able to deliver DNA molecules into the nucleus and cytoplasm at high
6 throughput with minimal cell damage. We anticipate that such direct and rapid nuclear delivery
7 will find utility in studies of fundamental biology and biomedical applications such as the
8 implementation of more robust DNA transfection for cell-based therapies. Future work will
9 focus on developing a deeper understanding of the interplay between the membrane disruptions,
10 electric field enhanced transportation, and the cell response, thus facilitate effective
11 implementation in more challenging cell types and applications. One would expect the parameter
12 space of DFE systems to be more complex than squeezing or electroporation alone as its efficacy
13 relies on the synergistic interplay of relevant parameters from both techniques. Nuclear envelope
14 disruptions in DFE can be explored further. Nevertheless, the DFE concept shows potential to
15 enable more rapid delivery and expression compared to existing transfection technologies, and
16 paves the way toward more targeted delivery strategies at the subcellular level.

17

1 **METHODS**

2 **Device Fabrication and Experimental Setup.** A silicon wafer was bonded to a Pyrex
3 wafer to form the DFE microfluidic device. Two major steps were involved in the fabrication:
4 (1) the fabrication of microfluidic channels on silicon wafer, and (2) the fabrication of
5 microfluidic electrodes on Pyrex wafer (see Supporting Information for more details). The
6 device was mounted onto a holder with inlet and outlet reservoirs (more details in ref. 29).
7 Electric pulses were generated from a function generator (Agilent 33220A) and gained through
8 an amplifier to drive the device through the wire bonded to the electrode pads using conductive
9 epoxy. Cells were suspended to a density of $1-5 \times 10^6$ cells/mL in a modified buffer (25mM
10 KCl, 0.85 mM K_2HPO_4 , 0.3mM KH_2PO_4 , 36mM myo-inositol, PH 7.2, conductivity 3.5mS/cm
11 at 25 °C, ref. 37) for experiment. Solutions of cells, mixed with desired delivery material, were
12 placed in the inlet reservoir. This reservoir was then connected to a compressed air line
13 controlled by a regulator. A pressure (0-20psi) was used to drive the fluid through the device,
14 and at the same time, electric pulses were applied to the device as cells flowed through. Cells
15 were collected from outlet reservoir and subjected to further treatment.

16
17 **Cell culture.** HeLa cell line (Hela-Kyoto) was provided by Hyman Lab, Max Planck Institute,
18 Dresden, Germany. Authentication Test was performed by Multiplex. Cells were routinely
19 cultured in 75 T flasks containing 20mL of DMEM culture medium supplemented with 10%
20 fetal bovine serum (FBS, Invitrogen 16000), at 37 °C in a humidified atmosphere containing 5%
21 CO_2 . hESCs (H13, WiCell, Wisconsin) were grown on an inactivated mouse embryonic
22 fibroblast (MEF) feeder layer, provided by Jeff Karp Lab in Brigham and Women's Hospital,
23 Harvard Medical School. mESCs (129P2/OlaHsd, provided by Richard Sherwood lab from
24 Brigham and Women's Hospital, Harvard Medical School) were maintained on gelatin-coated
25 plates in mESC medium composed of Knockout DMEM (Life Technologies) supplemented with
26 15% defined FBS (HyClone), 0.1 mM nonessential amino acids (Life Technologies), 1%
27 Glutamax (Life Technologies), 0.55 mM 2-mercaptoethanol (Sigma), $1 \times$ ESGRO LIF
28 (Millipore), 5 nM GSK-3 inhibitor XV and 500 nM UO126. Cells were regularly tested for
29 mycoplasma. HeLa cells expressing CHMP4B-GFP were a generous gift of the Tony Hyman lab

1 (43). They were maintained in geneticin-containing media and FACS sorted prior to
2 experiments.

3

4 **Delivery Materials.** Fluorescently labeled molecules, including dextran and plasmid DNA,
5 were mixed with cell solution at a concentration of 0.1 mg/mL. GFP DNA plasmid was used to
6 measure the DNA transfection.

7

8 **Flow Cytometry.** For quantitative analysis of cells after DNA delivery, cells were treated with
9 trypsin 24 hours after delivery experiment and washed twice with PBS (200 uL per well in V-
10 bottom 96-well plate). They were then resuspended in PBS solution supplemented with 3% FBS,
11 1% F-68 Pluronics, and 1 ug/mL propidium iodide (Sigma) for the analysis using LSR Fortessa
12 (BD Biosceinces).

13

14 **Lipofection.** Lipofectamine 2000 DNA transfection kit was used to represent Lipofection
15 technique. The DNA-lipid complex was prepared by combining 2 uL of Lipofection 2000
16 reagent in 100 uL of Opti-MEM medium with 2 ug of DNA plasmid in 100 uL of Opti-MEM
17 medium, followed by 5 minutes of incubation in room temperature. The DNA-lipid complex
18 solution was added to cell sample at the ratio of 1:30. More details can be found in the product
19 protocol (Lipofection 2000, Life Technologies).

20

21 **Microinjection.** The microinjection of DNA plasmid into Hela cells was operated by
22 experienced staff. 30 cells were injected for each condition. The DNA concentration in the buffer
23 for injection is 0.1 ug/mL. A pressure of 60hPa and a duration of 0.2 s were used for each
24 injection.

25

26 Data availability. The authors declare that all data supporting the findings of this study are
27 available within the paper and the Supplementary Information.

28 **Acknowledgements.** We thank Peimin Qi from Division of Comparative Medicine at MIT
29 for performing the microinjection, thank Dr. Qing Chen from Richard Sherwood lab at Brigham
30 and Women's Hospital for providing mouse embryonic stem cells, and thank Dr. Xiaolei Yin

1 from Jeff Karp Lab at David Koch Institute for Integrative Cancer Research at MIT for providing
2 human embryonic stem cells. The assistance and expertise of Glenn Paradis and personnel in the
3 flow cytometry core at the Koch Institute and the Microsystem Technology Laboratory at MIT
4 are highly acknowledged. This research was supported by National Institutes of Health
5 (R01GM101420-01A1), and device fabrication was performed at the Microsystem Technology
6 Laboratory at MIT.

7
8 AS, RL, and KFJ have a financial interest in SQZ Biotechnologies.

9 **Author Contributions:** X.D., M.S., A.S., R.L, and K.J. designed the research, X.D. and M.S.
10 performed the experiments, X.D. fabricated the devices. X.D. M.S., A.S., J.W., R.L., and K.J.
11 analyzed the data. X. D., M. S., A. S., J.W., R. L., and K. J. wrote the article.

12

1 **References**

- 2 1. Yin, H. *et al.* Non-viral vectors for gene-based therapy. *Nat Rev Genet* **15**, 541-555, (2014).
- 3 2. Maude, S. L. *et al.* Chimeric antigen receptor T cells for sustained remissions in leukemia. *The New*
4 *England journal of medicine* **371**, 1507-1517, (2014).
- 5 3. Stewart, M. P., Sharei, A., Ding, X., Sahay, G., Langer, R., & Jensen, K. F. In vitro and ex vivo
6 strategies for intracellular delivery. *Nature*, *538*, 183-192, (2016).
- 7 4. Nayak, S. & Herzog, R. W. Progress and prospects: immune responses to viral vectors. *Gene Ther.* *17*,
8 295–304 (2010).
- 9 5. Wu, S. C., Huang, G. Y. L. & Liu, J. H. Production of retrovirus and adenovirus vectors for gene
10 therapy: a comparative study using microcarrier and stationary cell culture. *Biotechnol. Progr.* *18*,
11 617–622 (2002).
- 12 6. Schmid, R. M. *et al.* Liposome mediated gene transfer into the rat oesophagus. *Gut* *41*, 549–556
13 (1997).
- 14 7. Lee, H. *et al.* Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA
15 delivery. *Nat. Nanotechnol.* *7*, 389–393 (2012).
- 16 8. O'Brien, J. A. & Lummis, S. C. R. Biolistic transfection of neuronal cultures using a hand-held gene
17 gun. *Nature Protoc.* *1*, 977–981 (2006).
- 18 9. Wells, D. J. Gene therapy progress and prospects: electroporation and other physical methods. *Gene*
19 *Ther.* *11*, 1363–1369 (2004).
- 20 10. Meacham, J. M., Durvasula, K., Degertekin, F. L. & Fedorov, A. G. Physical methods for
21 intracellular delivery: practical aspects from laboratory use to industrial-scale processing. *J. Lab.*
22 *Autom.* *19*, 1–18 (2014).
- 23 11. Capecchi, M. R. High efficiency transformation by direct microinjection of DNA into cultured
24 mammalian cells. *Cell* *22*, 479–488 (1980).
- 25 12. Nagy, A., Gertsenstein, M., Vintersten, K. & Behringer, R. *Manipulating the Mouse Embryo: A*
26 *Laboratory Manual* (Cold Spring Laboratory, 2003).
- 27 13. Wolff, J. A., & Budker, V. The mechanism of naked DNA uptake and expression. *Adv Genet.* *54*, 3–
28 20 (2005).
- 29 14. Neumann, E., Schaefer-Ridder, M., Wang, Y. & Hofschneider, P. H. Gene transfer into mouse lyoma
30 cells by electroporation in high electric fields. *EMBO J.* *1*, 841–845 (1982).
- 31 15. Escoffre, J.-M. *et al.* What is (still not) known of the mechanism by which electroporation mediates
32 gene transfer and expression in cells and tissues. *Mol. Biotechnol.* *41*, 286–95 (2009).
- 33 16. Vasilkoski, Z., Esser, A. T., Gowrishankar, T. R. & Weaver, J. C. Membrane electroporation: The
34 absolute rate equation and nanosecond time scale pore creation. *Phys. Rev. E* *74*, 021904 (2006).
- 35 17. Klenchin, V. A., Sukharev, S., Serov, S. M., Chernomordik, L. V & Chizmadzhev, Y. A. Electrically
36 induced DNA uptake by cells is a fast process involving DNA electrophoresis. *Biophys J.* *60*, (1991).

- 1 18. Weaver, J. C., Smith, K. C., Esser, A. T., Son, R. S. & Gowrishankar, T. R. A brief overview of
2 electroporation pulse strength-duration space: a region where additional intracellular effects are
3 expected. *Bioelectrochemistry* 87, 236–43 (2012).
- 4 19. Jordan, C. A., Neumann, E., & Sowers, A. E. (Eds.). (2013). *Electroporation and electrofusion in cell*
5 *biology*. Springer Science & Business Media.
- 6 20. Golzio, M., Teissie, J. & Rols, M.-P. Direct visualization at the single-cell level of electrically
7 mediated gene delivery. *Proc. Natl. Acad. Sci. USA* 99, 1292–1297 (2002).
- 8 21. Paganin-Gioanni, A *et al.* Direct visualization at the single-cell level of siRNA electrotransfer into
9 cancer cells. *Proc. Natl. Acad. Sci. USA* 108, 10443–7 (2011).
- 10 22. Rosazza, C. *et al.* Intracellular Tracking of Single-plasmid DNA Particles After Delivery by
11 Electroporation. *Mol. Ther.* 21, 2217–2226 (2013).
- 12 23. Boukany, P. E. *et al.* Nanochannel electroporation delivers precise amounts of biomolecules into
13 living cells. *Nat. Nanotechnol.* 6, 747–54 (2011).
- 14 24. Teissie, J., Golzio, M. & Rols, M. P. Mechanisms of cell membrane electropermeabilization: a
15 minireview of our present (lack of ?) knowledge. *Biochim. Biophys. Acta* 1724, 270–80 (2005).
- 16 25. Yarmush, M. L., Golberg, A., Serša, G., Kotnik, T. & Miklavčič, D. Electroporation-based
17 technologies for medicine: principles, applications, and challenges. *Annu. Rev. Biomed. Eng.* 16,
18 295–320 (2014).
- 19 26. Geng, T. & Lu, C. Microfluidic electroporation for cellular analysis and delivery. *Lab Chip* 13,
20 3803–21 (2013).
- 21 27. Lechardeur, D., Verkman, a & Lukacs, G. Intracellular routing of plasmid DNA during non-viral
22 gene transfer. *Adv. Drug Deliv. Rev.* 57, 755–767 (2005).
- 23 28. M.E. Dowty, P. Williams, G. Zhang, J.E. Hangstrom, J.A. Wolff, Plasmid DNA entry into post-
24 mitotic nuclei of primary rat myotubes, *Proc. Natl. Acad. Sci. USA* 92, 4572–4576(1995).
- 25 29. Shalek, A. K. *et al.* Vertical silicon nanowires as a universal platform for delivering biomolecules
26 into living cells. *Proc. Natl. Acad. Sci. USA* 107, 1870–5 (2010).
- 27 30. Xie, X. *et al.* Nanostraw–Electroporation System for Highly Efficient Intracellular Delivery and
28 Transfection. *ACS Nano* 4351–4358 (2013).
- 29 31. Wang, Y. *et al.* Poking cells for efficient vector-free intracellular delivery. *Nat. Commun.* 5, 4466
30 (2014).
- 31 32. Sharei, a. *et al.* A vector-free microfluidic platform for intracellular delivery. *Proc. Natl. Acad. Sci.*
32 *USA* 110, 2082–2087 (2013).
- 33 33. Lee, J., Sharei, A., Sim, W. Y., Adamo, A., Langer, R., Jensen, K. F., & Bawendi, M. G.
34 Nonendocytic delivery of functional engineered nanoparticles into the cytoplasm of live cells using a
35 novel, high-throughput microfluidic device. *Nano letters*, 12, 6322–6327 (2012).
- 36 34. Kollmannsperger, A. *et al.* Live-cell protein labelling with nanometre precision by cell
37 squeezing. *Nat. Commun.* 7:10372 doi: 10.1038/ncomms10372 (2016).

- 1 35. Szeto, G.L. *et al.* Microfluidic squeezing for intracellular antigen loading in polyclonal B-
2 cells as cellular vaccines. *Sci. Rep.* 5, 10276; doi: 10.1038/srep10276 (2015).
- 3 36. A. J. Jimenez, P. Maiuri, J. Lafaurie-Janvore, S. Divoux, M. Piel, F. Perez, ESCRT machinery is
4 required for plasma membrane repair. *Science* 343, 1247136 (2014).
- 5 37. Raab, M. *et al.* ESCRT III repairs nuclear envelope ruptures during cell migration to limit DNA
6 damage and cell death. *Science* **352**, 359–62 (2016).
- 7 38. Denais, C.M. Gilbert, R. M. Isermann, P. McGregor, A. L. Lindert, M. te Weigel, B. Davidson, P.
8 M. Friedl, P. Wolf, K., Nuclear envelope rupture and repair during cancer cell migration. *Science*
9 **352**, 353–358 (2016).
- 10 39. Y. Olmos, L. Hodgson, J. Mantell, P. Verkade, J. G. Carlton, ESCRT-III controls nuclear envelope
11 reformation. *Nature* 522, 236–239 (2015).
- 12 40. Groulx, N., Boudreault, F., Orlov, S. N., & Grygorczyk, R. Membrane reserves and hypotonic cell
13 swelling. *The Journal of membrane biology*, 214, 43-56, (2006).
- 14 41. Wei, Z. *et al.* A laminar flow electroporation system for efficient DNA and siRNA delivery. *Anal.*
15 *Chem.* 83, 5881–5887 (2011).
- 16 42. Son, R.S., Gowrishankar, T. R., Smith, K. C., and Weaver, J. C. Modeling a conventional
17 electroporation pulse train: decreased pore number, cumulative calcium transport and an example of
18 electrosensitization (Epub ahead of print). *Transactions in Biomedical Engineering*, 2015.
- 19 43. Poser, I., *et al.* BAC TransgeneOmics: a high-throughput method for exploration of protein function
20 in mammals. *Nature methods*, 5(5), 409-415, (2008).
- 21

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

Fig. 1. Device structure and working mechanism. **(a)** Schematic drawing illustrating the working principle: (i) mechanical disruption of the cell membrane as the cell passes through the constriction, and (ii) subsequent electric pulses driving DNA into the cytoplasm and nucleus through the disrupted membrane. **(b)** Magnification of a set of identical parallel microfluidic constriction etched into a silicon wafer (left), and a set of electrodes deposited on a Pyrex wafer (right). **(c)** An optical image of a finished device realized by bonding silicon and Pyrex wafers. The scale bar is 1 mm. Details of device fabrication are in Figure S1.

Fig. 2. DNA transfection performance and expression dynamics depend on the applied electric field and methods. DNA transfection efficiency **(a)** and cell viability **(b)** at 24 h after treatment as a function of applied electric amplitude (voltage). The introduction of mechanical disruption prior electrical delivery significantly enhances the DNA transfection, while bringing negligible damage to cell viability. GFP plasmid DNA transfection efficiency and cell viability were measured by flow cytometry 24 hours after delivery treatment using propidium iodide staining. **(c)** GFP expression efficiency as a function of time post treatment. Efficiency is defined as the GFP expressing cells over total live cells after treatment. A 10-7 chip is used for mechanical disruption (S: cell squeeze) and DFE. A pulse of 0.1ms/10V at a frequency of 200Hz is used for flow EP (Microfluidic based flow electroporation), and a single pulse of 15ms/15000V is used in EP. **(d)** The dynamics of DNA expression is analyzed by measuring differential GFP expressing at different time points after treatment. More than 80% of transfected cells expressed GFP within 1 h after treatment in microinjection and DFE. In contrast, most of transfected cells in flow EP (60%), EP (70%) and LP2000 (95%) express GFP 4 – 48 h after treatment. The number of HeLa cells in every treatment for each method is shown as well, indicating the throughput of each technique. Each data point is the mean value of triplicate and error bars represent \pm s.d.

Fig. 3. Visualization of the delivery of fluorescence labeled plasmid DNA (LDNA) to HeLa cells. After nucleus and plasma membrane staining, Cells were mixed with Cy3 labeled plasmid DNA before transfection. After treatment, cells were washed with OPTI MEM, fixed with cell fixation kit, and ready for confocal imaging. **(a)** by only cell squeezing (S), no LDNA signal was detected in the cell, A 10-7 chip was used at cell speed of 500mm/s. **(b)** in electroporation (EP), an electric pulse of 15ms/1200V was applied using NEON electroporation system. DNA accumulation was found on the plasma membrane. **(c)** in DFE, a significant Cy3 fluorescence was observed filling cytoplasm and nucleus. 10-7 DFE chip was used at cell speed of 500mm/s with applied electric pulse of 0.1ms (200Hz) at 10 V. Labeled DNA was detected in plasma membrane, cytoplasm and nucleus. **(d)**, Relative fluorescence intensity profile over the dashed line across single cells in **a**, **b**, and **c**, shows the labeled DNA molecule distribution after treatments of squeezing (S), EP, and DFE. Scale bar is 10 μ m. Original confocal fluorescent images are shown.

Fig. 4. ESCRT-III recruitment for plasma membrane and nuclear envelope repair. CHMP4B-GFP expressing HeLa cells were stained with DAPI to visualize the nucleus before treatment. After treatments of squeezing (S), EP, or DFE, cells were incubated in culture media, and fixed with a cell fixation kit at 0.5, 1.5, 2.5, 3.5, 5.5, 10, and 15 minutes after treatment, and processed for confocal imaging. **(a)** Confocal images of representative cells at 1.5 minutes after no treatment (NC, Negative Control), squeezing (S), electroporation (EP), and DFE. CHMP4B-GFP foci are visible at both plasma membrane and nuclear envelope in DFE, but only at the plasma membrane in S and EP. Number of CHMP4B-GFP foci at plasma membrane **(b)** and nuclear envelope **(c)** after treatment of S, EP and DFE (10 cells at each data point). Original confocal fluorescent images are shown. Each data point represents the mean value of 10 cells and error bars represent \pm s.d..